Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
Innovation & Entrepreneurship
Strategy / MBA Resources
Case Study SWOT Analysis Solution
Case Study Description of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets
This case explores the difficulties involved in commercialising vaccines in low-income settings. The focus is the dengue vaccine, launched at the end of 2015, which was first commercialised in emerging markets. It considers issues of affordability and distribution, higlighting the need for business model innovation in all industries.
Swot Analysis of "Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets" written by Philip Parker, Pierfitte Marion includes – strengths weakness that are internal strategic factors of the organization, and opportunities and threats that Vaccine Dengue facing as an external strategic factors. Some of the topics covered in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets case study are - Strategic Management Strategies, Health and Innovation & Entrepreneurship.
Some of the macro environment factors that can be used to understand the Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets casestudy better are - – increasing government debt because of Covid-19 spendings, technology disruption, increasing transportation and logistics costs, increasing household debt because of falling income levels, increasing inequality as vast percentage of new income is going to the top 1%, there is backlash against globalization, supply chains are disrupted by pandemic ,
competitive advantages are harder to sustain because of technology dispersion, digital marketing is dominated by two big players Facebook and Google, etc
Introduction to SWOT Analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets
SWOT stands for an organization’s Strengths, Weaknesses, Opportunities and Threats . At Oak Spring University , we believe that protagonist in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets case study can use SWOT analysis as a strategic management tool to assess the current internal strengths and weaknesses of the Vaccine Dengue, and to figure out the opportunities and threats in the macro environment – technological, environmental, political, economic, social, demographic, etc in which Vaccine Dengue operates in.
According to Harvard Business Review, 75% of the managers use SWOT analysis for various purposes such as – evaluating current scenario, strategic planning, new venture feasibility, personal growth goals, new market entry, Go To market strategies, portfolio management and strategic trade-off assessment, organizational restructuring, etc.
SWOT Objectives / Importance of SWOT Analysis and SWOT Matrix
SWOT analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets can be done for the following purposes –
1. Strategic planning using facts provided in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets case study
2. Improving business portfolio management of Vaccine Dengue
3. Assessing feasibility of the new initiative in Innovation & Entrepreneurship field.
4. Making a Innovation & Entrepreneurship topic specific business decision
5. Set goals for the organization
6. Organizational restructuring of Vaccine Dengue
Strengths Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets | Internal Strategic Factors
What are Strengths in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The strengths of Vaccine Dengue in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets Harvard Business Review case study are -
High switching costs
– The high switching costs that Vaccine Dengue has built up over years in its products and services combo offer has resulted in high retention of customers, lower marketing costs, and greater ability of the firm to focus on its customers.
Learning organization
- Vaccine Dengue is a learning organization. It has inculcated three key characters of learning organization in its processes and operations – exploration, creativity, and expansiveness. The work place at Vaccine Dengue is open place that encourages instructiveness, ideation, open minded discussions, and creativity. Employees and leaders in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets Harvard Business Review case study emphasize – knowledge, initiative, and innovation.
Strong track record of project management
– Vaccine Dengue is known for sticking to its project targets. This enables the firm to manage – time, project costs, and have sustainable margins on the projects.
Sustainable margins compare to other players in Innovation & Entrepreneurship industry
– Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets firm has clearly differentiated products in the market place. This has enabled Vaccine Dengue to fetch slight price premium compare to the competitors in the Innovation & Entrepreneurship industry. The sustainable margins have also helped Vaccine Dengue to invest into research and development (R&D) and innovation.
Operational resilience
– The operational resilience strategy in the Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets Harvard Business Review case study comprises – understanding the underlying the factors in the industry, building diversified operations across different geographies so that disruption in one part of the world doesn’t impact the overall performance of the firm, and integrating the various business operations and processes through its digital transformation drive.
Digital Transformation in Innovation & Entrepreneurship segment
- digital transformation varies from industry to industry. For Vaccine Dengue digital transformation journey comprises differing goals based on market maturity, customer technology acceptance, and organizational culture. Vaccine Dengue has successfully integrated the four key components of digital transformation – digital integration in processes, digital integration in marketing and customer relationship management, digital integration into the value chain, and using technology to explore new products and market opportunities.
Organizational Resilience of Vaccine Dengue
– The covid-19 pandemic has put organizational resilience at the centre of everthing that Vaccine Dengue does. Organizational resilience comprises - Financial Resilience, Operational Resilience, Technological Resilience, Organizational Resilience, Business Model Resilience, and Reputation Resilience.
Diverse revenue streams
– Vaccine Dengue is present in almost all the verticals within the industry. This has provided firm in Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets case study a diverse revenue stream that has helped it to survive disruptions such as global pandemic in Covid-19, financial disruption of 2008, and supply chain disruption of 2021.
High brand equity
– Vaccine Dengue has strong brand awareness and brand recognition among both - the exiting customers and potential new customers. Strong brand equity has enabled Vaccine Dengue to keep acquiring new customers and building profitable relationship with both the new and loyal customers.
Ability to lead change in Innovation & Entrepreneurship field
– Vaccine Dengue is one of the leading players in its industry. Over the years it has not only transformed the business landscape in its segment but also across the whole industry. The ability to lead change has enabled Vaccine Dengue in – penetrating new markets, reaching out to new customers, and providing different value propositions to different customers in the international markets.
Superior customer experience
– The customer experience strategy of Vaccine Dengue in the segment is based on four key concepts – personalization, simplification of complex needs, prompt response, and continuous engagement.
Low bargaining power of suppliers
– Suppliers of Vaccine Dengue in the sector have low bargaining power. Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets has further diversified its suppliers portfolio by building a robust supply chain across various countries. This helps Vaccine Dengue to manage not only supply disruptions but also source products at highly competitive prices.
Weaknesses Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets | Internal Strategic Factors
What are Weaknesses in SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The weaknesses of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets are -
Products dominated business model
– Even though Vaccine Dengue has some of the most successful products in the industry, this business model has made each new product launch extremely critical for continuous financial growth of the organization. firm in the HBR case study - Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets should strive to include more intangible value offerings along with its core products and services.
Slow decision making process
– As mentioned earlier in the report, Vaccine Dengue has a very deliberative decision making approach. This approach has resulted in prudent decisions, but it has also resulted in missing opportunities in the industry over the last five years. Vaccine Dengue even though has strong showing on digital transformation primary two stages, it has struggled to capitalize the power of digital transformation in marketing efforts and new venture efforts.
High bargaining power of channel partners
– Because of the regulatory requirements, Philip Parker, Pierfitte Marion suggests that, Vaccine Dengue is facing high bargaining power of the channel partners. So far it has not able to streamline the operations to reduce the bargaining power of the value chain partners in the industry.
High dependence on star products
– The top 2 products and services of the firm as mentioned in the Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets HBR case study still accounts for major business revenue. This dependence on star products in has resulted into insufficient focus on developing new products, even though Vaccine Dengue has relatively successful track record of launching new products.
High operating costs
– Compare to the competitors, firm in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets has high operating costs in the. This can be harder to sustain given the new emerging competition from nimble players who are using technology to attract Vaccine Dengue 's lucrative customers.
Skills based hiring
– The stress on hiring functional specialists at Vaccine Dengue has created an environment where the organization is dominated by functional specialists rather than management generalist. This has resulted into product oriented approach rather than marketing oriented approach or consumers oriented approach.
Compensation and incentives
– The revenue per employee as mentioned in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets, is just above the industry average. Vaccine Dengue needs to redesign the compensation structure and incentives to increase the revenue per employees. Some of the steps that it can take are – hiring more specialists on project basis, etc.
Ability to respond to the competition
– As the decision making is very deliberative, highlighted in the case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets, in the dynamic environment Vaccine Dengue has struggled to respond to the nimble upstart competition. Vaccine Dengue has reasonably good record with similar level competitors but it has struggled with new entrants taking away niches of its business.
Low market penetration in new markets
– Outside its home market of Vaccine Dengue, firm in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets needs to spend more promotional, marketing, and advertising efforts to penetrate international markets.
Increasing silos among functional specialists
– The organizational structure of Vaccine Dengue is dominated by functional specialists. It is not different from other players in the Innovation & Entrepreneurship segment. Vaccine Dengue needs to de-silo the office environment to harness the true potential of its workforce. Secondly the de-silo will also help Vaccine Dengue to focus more on services rather than just following the product oriented approach.
Employees’ incomplete understanding of strategy
– From the instances in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets, it seems that the employees of Vaccine Dengue don’t have comprehensive understanding of the firm’s strategy. This is reflected in number of promotional campaigns over the last few years that had mixed messaging and competing priorities. Some of the strategic activities and services promoted in the promotional campaigns were not consistent with the organization’s strategy.
Opportunities Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets | External Strategic Factors
What are Opportunities in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The opportunities highlighted in the Harvard Business Review case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets are -
Reforming the budgeting process
- By establishing new metrics that will be used to evaluate both existing and potential projects Vaccine Dengue can not only reduce the costs of the project but also help it in integrating the projects with other processes within the organization.
Creating value in data economy
– The success of analytics program of Vaccine Dengue has opened avenues for new revenue streams for the organization in the industry. This can help Vaccine Dengue to build a more holistic ecosystem as suggested in the Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets case study. Vaccine Dengue can build new products and services such as - data insight services, data privacy related products, data based consulting services, etc.
Remote work and new talent hiring opportunities
– The widespread usage of remote working technologies during Covid-19 has opened opportunities for Vaccine Dengue to expand its talent hiring zone. According to McKinsey Global Institute, 20% of the high end workforce in fields such as finance, information technology, can continously work from remote local post Covid-19. This presents a really great opportunity for Vaccine Dengue to hire the very best people irrespective of their geographical location.
Buying journey improvements
– Vaccine Dengue can improve the customer journey of consumers in the industry by using analytics and artificial intelligence. Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets suggest that firm can provide automated chats to help consumers solve their own problems, provide online suggestions to get maximum out of the products and services, and help consumers to build a community where they can interact with each other to develop new features and uses.
Harnessing reconfiguration of the global supply chains
– As the trade war between US and China heats up in the coming years, Vaccine Dengue can build a diversified supply chain model across various countries in - South East Asia, India, and other parts of the world. This reconfiguration of global supply chain can help, as suggested in case study, Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets, to buy more products closer to the markets, and it can leverage its size and influence to get better deal from the local markets.
Redefining models of collaboration and team work
– As explained in the weaknesses section, Vaccine Dengue is facing challenges because of the dominance of functional experts in the organization. Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets case study suggests that firm can utilize new technology to build more coordinated teams and streamline operations and communications using tools such as CAD, Zoom, etc.
Manufacturing automation
– Vaccine Dengue can use the latest technology developments to improve its manufacturing and designing process in Innovation & Entrepreneurship segment. It can use CAD and 3D printing to build a quick prototype and pilot testing products. It can leverage automation using machine learning and artificial intelligence to do faster production at lowers costs, and it can leverage the growth in satellite and tracking technologies to improve inventory management, transportation, and shipping.
Leveraging digital technologies
– Vaccine Dengue can leverage digital technologies such as artificial intelligence and machine learning to automate the production process, customer analytics to get better insights into consumer behavior, realtime digital dashboards to get better sales tracking, logistics and transportation, product tracking, etc.
Learning at scale
– Online learning technologies has now opened space for Vaccine Dengue to conduct training and development for its employees across the world. This will result in not only reducing the cost of training but also help employees in different part of the world to integrate with the headquarter work culture, ethos, and standards.
Use of Bitcoin and other crypto currencies for transactions
– The popularity of Bitcoin and other crypto currencies as asset class and medium of transaction has opened new opportunities for Vaccine Dengue in the consumer business. Now Vaccine Dengue can target international markets with far fewer capital restrictions requirements than the existing system.
Increase in government spending
– As the United States and other governments are increasing social spending and infrastructure spending to build economies post Covid-19, Vaccine Dengue can use these opportunities to build new business models that can help the communities that Vaccine Dengue operates in. Secondly it can use opportunities from government spending in Innovation & Entrepreneurship sector.
Building a culture of innovation
– managers at Vaccine Dengue can make experimentation a productive activity and build a culture of innovation using approaches such as – mining transaction data, A/B testing of websites and selling platforms, engaging potential customers over various needs, and building on small ideas in the Innovation & Entrepreneurship segment.
Better consumer reach
– The expansion of the 5G network will help Vaccine Dengue to increase its market reach. Vaccine Dengue will be able to reach out to new customers. Secondly 5G will also provide technology framework to build new tools and products that can help more immersive consumer experience and faster consumer journey.
Threats Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets External Strategic Factors
What are Threats in the SWOT Analysis / TOWS Matrix / Weighted SWOT Analysis
The threats mentioned in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets are -
Shortening product life cycle
– it is one of the major threat that Vaccine Dengue is facing in Innovation & Entrepreneurship sector. It can lead to higher research and development costs, higher marketing expenses, lower customer loyalty, etc.
Easy access to finance
– Easy access to finance in Innovation & Entrepreneurship field will also reduce the barriers to entry in the industry, thus putting downward pressure on the prices because of increasing competition. Vaccine Dengue can utilize it by borrowing at lower rates and invest it into research and development, capital expenditure to fortify its core competitive advantage.
High dependence on third party suppliers
– Vaccine Dengue high dependence on third party suppliers can disrupt its processes and delivery mechanism. For example -the current troubles of car makers because of chip shortage is because the chip companies started producing chips for electronic companies rather than car manufacturers.
Consumer confidence and its impact on Vaccine Dengue demand
– There is a high probability of declining consumer confidence, given – high inflammation rate, rise of gig economy, lower job stability, increasing cost of living, higher interest rates, and aging demography. All the factors contribute to people saving higher rate of their income, resulting in lower consumer demand in the industry and other sectors.
Capital market disruption
– During the Covid-19, Dow Jones has touched record high. The valuations of a number of companies are way beyond their existing business model potential. This can lead to capital market correction which can put a number of suppliers, collaborators, value chain partners in great financial difficulty. It will directly impact the business of Vaccine Dengue.
Technology acceleration in Forth Industrial Revolution
– Vaccine Dengue has witnessed rapid integration of technology during Covid-19 in the Innovation & Entrepreneurship industry. As one of the leading players in the industry, Vaccine Dengue needs to keep up with the evolution of technology in the Innovation & Entrepreneurship sector. According to Mckinsey study top managers believe that the adoption of technology in operations, communications is 20-25 times faster than what they planned in the beginning of 2019.
Trade war between China and United States
– The trade war between two of the biggest economies can hugely impact the opportunities for Vaccine Dengue in the Innovation & Entrepreneurship industry. The Innovation & Entrepreneurship industry is already at various protected from local competition in China, with the rise of trade war the protection levels may go up. This presents a clear threat of current business model in Chinese market.
Increasing international competition and downward pressure on margins
– Apart from technology driven competitive advantage dilution, Vaccine Dengue can face downward pressure on margins from increasing competition from international players. The international players have stable revenue in their home market and can use those resources to penetrate prominent markets illustrated in HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets .
Increasing wage structure of Vaccine Dengue
– Post Covid-19 there is a sharp increase in the wages especially in the jobs that require interaction with people. The increasing wages can put downward pressure on the margins of Vaccine Dengue.
Backlash against dominant players
– US Congress and other legislative arms of the government are getting tough on big business especially technology companies. The digital arm of Vaccine Dengue business can come under increasing regulations regarding data privacy, data security, etc.
Stagnating economy with rate increase
– Vaccine Dengue can face lack of demand in the market place because of Fed actions to reduce inflation. This can lead to sluggish growth in the economy, lower demands, lower investments, higher borrowing costs, and consolidation in the field.
Regulatory challenges
– Vaccine Dengue needs to prepare for regulatory challenges as consumer protection groups and other pressure groups are vigorously advocating for more regulations on big business - to reduce inequality, to create a level playing field, to product data privacy and consumer privacy, to reduce the influence of big money on democratic institutions, etc. This can lead to significant changes in the Innovation & Entrepreneurship industry regulations.
High level of anxiety and lack of motivation
– the Great Resignation in United States is the sign of broader dissatisfaction among the workforce in United States. Vaccine Dengue needs to understand the core reasons impacting the Innovation & Entrepreneurship industry. This will help it in building a better workplace.
Weighted SWOT Analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets Template, Example
Not all factors mentioned under the Strengths, Weakness, Opportunities, and Threats quadrants in the SWOT Analysis are equal. Managers in the HBR case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets needs to zero down on the relative importance of each factor mentioned in the Strengths, Weakness, Opportunities, and Threats quadrants.
We can provide the relative importance to each factor by assigning relative weights. Weighted SWOT analysis process is a three stage process –
First stage for doing weighted SWOT analysis of the case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets is to rank the strengths and weaknesses of the organization. This will help you to assess the most important strengths and weaknesses of the firm and which one of the strengths and weaknesses mentioned in the initial lists are marginal and can be left out.
Second stage for conducting weighted SWOT analysis of the Harvard case study Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets is to give probabilities to the external strategic factors thus better understanding the opportunities and threats arising out of macro environment changes and developments.
Third stage of constructing weighted SWOT analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets is to provide strategic recommendations includes – joining likelihood of external strategic factors such as opportunities and threats to the internal strategic factors – strengths and weaknesses. You should start with external factors as they will provide the direction of the overall industry. Secondly by joining probabilities with internal strategic factors can help the company not only strategic fit but also the most probably strategic trade-off that Vaccine Dengue needs to make to build a sustainable competitive advantage.
Feel free to connect with us if you need business research.
You can download Excel Template of Case Study Solution & Analysis of Dengue - Sustainable Large Scale Vaccine Delivery in Low-Income Markets (A): The Challenges of Vaccine Launches in Emerging Markets